 | Up a level |
2020
Wolf, J., Overbeck, T., Han, J. -Y., Hochmair, M., De Marinis, F., Ohashi, K., Smit, E. F., Power, D., Garon, E. B., Groen, H. J. M., Tan, D. S. W., Waldron-Lynch, M., Le Mouhaer, S., Nwana, N., Giovannini, M. and Heist, R. S. (2020). Capmatinib in patients with high-level MET-amplified advanced non-small cell lung cancer (NSCLC): results from the phase 2 GEOMETRY mono-1 study. Oncol. Res. Treat., 43 (SUPPL 4). S. 150 - 152. BASEL: KARGER. ISSN 2296-5262
2017
Wolf, J., Han, J., Nishio, M., Souquet, P., Paz-Ares, L., De Marinis, F., Seto, T., De Jonge, M., Kim, T. M., Vansteenkiste, J., Tan, D., Garon, E., Groen, H., Hochmair, M., Felip, E., Reguart, N., Thomas, M., Overbeck, T., Ohashi, K., Giovannini, M., Yura, R., Joshi, A., Akimov, M. and Heist, R. (2017). GEOMETRY Mono-1: Phase II, Multicenter Study of MET Inhibitor Capmatinib (INC280) in EGFR Wt, MET-Dysregulated Advanced NSCLC. J. Thorac. Oncol., 12 (11). S. S2399 - 1. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1556-1380
Wolf, J., Han, J., Nishio, M., Souquet, P., Paz-Ares, L., De Marinis, F., Seto, T., De Jonge, M., Kim, T. M., Vansteenkiste, J., Tan, D. S. W., Garon, E. B., Groen, H., Hochmair, M. J., Felip, E., Reguart, N., Thomas, M., Overbeck, T., Ohashi, K., Giovannini, M., Yura, R., Joshi, A., Akimov, M. and Heist, R. (2017). GEOMETRY Mono-1: Phase II, Multicenter Study of MET Inhibitor Capmatinib (INC280) in EGFR wt, MET-dysregulated Advanced NSCLC. J. Thorac. Oncol., 12 (11). S. S1578 - 2. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1556-1380
2015
Griesinger, F., Sebastian, M., Serke, M., Buettner, R., Waller, C., Reinmuth, N., Graeven, U., Lueers, A., Radke, S., Karatas, A., Heukamp, L., Tiemann, M. and Overbeck, T. (2015). Induction therapy with intercalated TKI and chemotherapy in NSCLC with activating EGFR mutation in stages II-IIIB: Neolntercal. Oncol. Res. Treat., 38. S. 140 - 141. BASEL: KARGER. ISSN 2296-5262